In July production of etretinate (Tigason – Roche) ceased and in its place the manufacturer is promoting acitretin (Neotigason – Roche). Like etretinate, acitretin is marketed for the treatment in hospital of patients with severe, extensive, resistant psoriasis and for palmoplantar pustular psoriasis, severe congenital ichthyosis or severe Darier’s disease (keratosis follicularis). Does acitretin offer any advantage?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.